TABLE 2

Clinical features and course of hVISA versus VSSA infection

CharacteristicaValue for the cohortP value
hVISA (n = 29)VSSA (n = 58)
Type of pneumonia (no. of patients [%])
    Community acquired6 (20.7)12 (20.7)1.000
    Health care associated12 (41.4)24 (41.4)1.000
    Hospital acquired5 (17.2)8 (13.7)0.753
    Ventilator associated6 (20.7)14 (24.1)0.792
Antibiotic therapy (no. of patients [%])
    Vancomycin15 (51.7)38 (65.5)0.214
    Linezolid8 (29.6)12 (20.7)0.416
    Ceftaroline3 (10.3)3 (5.2)0.395
    TMP/SMX1 (3.4)2 (3.4)1.000
Median time (h) to change in therapy (IQR)66.6 (32.3–109.2)72.8 (38.7–160.4)0.263
Median (IQR) LOS (days)b17.5 (11.0–30.5)17.5 (11.0–35.8)0.554
Median (IQR) LOSPNA (days)b13 (7–24)11 (6–18)0.797
ID consult (no. of patients [%])16 (55.2)34 (58.6)0.717
Concurrent bacteremia (no. of patients [%])27 (93.1)52 (89.7)0.742
Median (IQR) duration of bacteremia (days)2 (1–5)2 (1–5)0.901
Presence of concurrent sites of infection (no. of patients [%])
    Skin/soft tissue7 (24.1)8 (13.8)0.229
    Deep abscess1 (3.4)0 (0.0)0.155
    Bone/joint2 (6.9)1 (1.7)0.213
    Infective endocarditis2 (6.9)2 (3.4)0.469
    Unknown2 (6.9)10 (17.2)0.187
ICU admission by type (no. of patients [%])23 (79.3)40 (70.7)0.390
    Burn/trauma6 (26.1)5 (12.5)0.187
    Medical15 (65.2)31 (77.5)0.379
    Surgical2 (8.7)5 (12.5)1.000
Median (IQR) ICU LOS (days)b12 (5.5–22.5)13 (5.0–25.0)0.725
Mechanical ventilation (any) (no. of patients [%])18 (62.1)37 (63.8)0.875
Presence of S. aureus isolate type (no. of patients [%])
    PVL positive6 (20.7)17 (29.3)0.390
    USA3006 (20.7)16 (27.6)0.485
    SCCmec type II12 (41.4)25 (43.1)0.878
    agr group II16 (55.2)25 (43.1)0.288
    agr dysfunction12 (41.4)19 (32.8)0.429
Presence of other respiratory pathogens (no. of patients [%])
    Acinetobacter spp.5 (17.2)6 (10.3)0.642
    Pseudomonas spp.5 (17.2)5 (8.6)0.362
    Klebsiella spp.1 (3.4)7 (12.1)0.190
    Streptococcal spp.2 (6.9)4 (6.9)1.000
  • a IQR, interquartile range; LOS, length of stay; LOSPNA, length of stay postdiagnosis of pneumonia; ICU, intensive care unit; PVL, Panton-Valentine leukocidin; TMP/SMX, trimethoprim-sulfamethoxazole.

  • b Censored for inpatient mortality.